Do analysts rate TLSA or ATOS?

Atossa Genetics has a consensus target price of $24.50, suggesting a potential upside of 456.82%. Given Atossa Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Atossa Genetics is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Atossa Genetics 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation & earnings, TLSA or ATOS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tiziana Life Sciences N/A N/A -$18.43M N/A N/A Atossa Genetics N/A N/A -$34.77M -$3.21 N/A

Is TLSA or ATOS more profitable?

Tiziana Life Sciences' return on equity of 0.00% beat Atossa Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Tiziana Life Sciences N/A N/A N/A Atossa Genetics N/A -84.91% -72.36%

Does the media prefer DERM or ATOS?

In the previous week, Atossa Genetics had 1 more articles in the media than Journey Medical. MarketBeat recorded 3 mentions for Atossa Genetics and 2 mentions for Journey Medical. Journey Medical's average media sentiment score of 0.63 beat Atossa Genetics' score of 0.28 indicating that Journey Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Journey Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atossa Genetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ATOS or IFRX more profitable?

Atossa Genetics' return on equity of -84.91% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets Atossa Genetics N/A -84.91% -72.36% InflaRx N/A -88.30% -65.77%

Does the media favor ATOS or IFRX?

In the previous week, Atossa Genetics had 1 more articles in the media than InflaRx. MarketBeat recorded 3 mentions for Atossa Genetics and 2 mentions for InflaRx. InflaRx's average media sentiment score of 1.79 beat Atossa Genetics' score of 0.28 indicating that InflaRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atossa Genetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral InflaRx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger valuation & earnings, OKUR or ATOS?

Atossa Genetics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OnKure Therapeutics N/A N/A -$59.52M -$4.33 N/A Atossa Genetics N/A N/A -$34.77M -$3.21 N/A

Is OKUR or ATOS more profitable?

OnKure Therapeutics' return on equity of -61.02% beat Atossa Genetics' return on equity. Company Net Margins Return on Equity Return on Assets OnKure Therapeutics N/A -61.02% -55.99% Atossa Genetics N/A -84.91% -72.36%

Does the media prefer OKUR or ATOS?

In the previous week, OnKure Therapeutics had 1 more articles in the media than Atossa Genetics. MarketBeat recorded 4 mentions for OnKure Therapeutics and 3 mentions for Atossa Genetics. OnKure Therapeutics' average media sentiment score of 0.89 beat Atossa Genetics' score of 0.28 indicating that OnKure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OnKure Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atossa Genetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Atossa Genetics (ATOS) Competitors

$4.40 -0.01 (-0.23%)

Closing price 04:00 PM Eastern

Extended Trading

$4.44 +0.04 (+0.89%)

As of 07:33 PM Eastern

Compare

ATOS vs. DTIL, TLSA, DERM, IFRX, and OKUR

Should you buy Atossa Genetics stock or one of its competitors? MarketBeat compares Atossa Genetics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Atossa Genetics include Precision BioSciences (DTIL), Tiziana Life Sciences (TLSA), Journey Medical (DERM), InflaRx (IFRX), and OnKure Therapeutics (OKUR). These companies are all part of the "pharmaceutical products" industry.

How does Atossa Genetics compare to Precision BioSciences?

Precision BioSciences (NASDAQ:DTIL) and Atossa Genetics (NASDAQ:ATOS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

Precision BioSciences has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market.

Precision BioSciences currently has a consensus price target of $32.25, indicating a potential upside of 400.00%. Atossa Genetics has a consensus price target of $24.50, indicating a potential upside of 456.82%. Given Atossa Genetics' higher possible upside, analysts plainly believe Atossa Genetics is more favorable than Precision BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are held by institutional investors. 2.7% of Precision BioSciences shares are held by insiders. Comparatively, 9.8% of Atossa Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Atossa Genetics has lower revenue, but higher earnings than Precision BioSciences. Precision BioSciences is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$34.26M	4.86	-$45.72M	-$3.67	N/A
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A

In the previous week, Atossa Genetics had 1 more articles in the media than Precision BioSciences. MarketBeat recorded 3 mentions for Atossa Genetics and 2 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 1.44 beat Atossa Genetics' score of 0.28 indicating that Precision BioSciences is being referred to more favorably in the media.

Company	Overall Sentiment
Precision BioSciences	Positive
Atossa Genetics	Neutral

Atossa Genetics has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Atossa Genetics' return on equity of -84.91% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-85.37%	-37.34%
Atossa Genetics	N/A	-84.91%	-72.36%

Summary

Atossa Genetics beats Precision BioSciences on 8 of the 15 factors compared between the two stocks.

How does Atossa Genetics compare to Tiziana Life Sciences?

Tiziana Life Sciences (NASDAQ:TLSA) and Atossa Genetics (NASDAQ:ATOS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

In the previous week, Atossa Genetics had 2 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 3 mentions for Atossa Genetics and 1 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 1.87 beat Atossa Genetics' score of 0.28 indicating that Tiziana Life Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Tiziana Life Sciences	Very Positive
Atossa Genetics	Neutral

Tiziana Life Sciences' return on equity of 0.00% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
Atossa Genetics	N/A	-84.91%	-72.36%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A

Atossa Genetics has a consensus target price of $24.50, suggesting a potential upside of 456.82%. Given Atossa Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Atossa Genetics is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tiziana Life Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

12.7% of Atossa Genetics shares are owned by institutional investors. 39.8% of Tiziana Life Sciences shares are owned by insiders. Comparatively, 9.8% of Atossa Genetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Tiziana Life Sciences has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market.

Summary

Atossa Genetics beats Tiziana Life Sciences on 6 of the 11 factors compared between the two stocks.

How does Atossa Genetics compare to Journey Medical?

Journey Medical (NASDAQ:DERM) and Atossa Genetics (NASDAQ:ATOS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

Journey Medical has higher revenue and earnings than Atossa Genetics. Journey Medical is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Journey Medical	$61.86M	2.70	-$11.43M	-$0.37	N/A
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A

7.3% of Journey Medical shares are owned by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are owned by institutional investors. 15.0% of Journey Medical shares are owned by insiders. Comparatively, 9.8% of Atossa Genetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Atossa Genetics had 1 more articles in the media than Journey Medical. MarketBeat recorded 3 mentions for Atossa Genetics and 2 mentions for Journey Medical. Journey Medical's average media sentiment score of 0.63 beat Atossa Genetics' score of 0.28 indicating that Journey Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Journey Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atossa Genetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Journey Medical currently has a consensus price target of $13.00, suggesting a potential upside of 114.17%. Atossa Genetics has a consensus price target of $24.50, suggesting a potential upside of 456.82%. Given Atossa Genetics' higher possible upside, analysts clearly believe Atossa Genetics is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Journey Medical has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market.

Atossa Genetics has a net margin of 0.00% compared to Journey Medical's net margin of -14.82%. Journey Medical's return on equity of -35.57% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Journey Medical	-14.82%	-35.57%	-10.88%
Atossa Genetics	N/A	-84.91%	-72.36%

Summary

Journey Medical beats Atossa Genetics on 8 of the 13 factors compared between the two stocks.

How does Atossa Genetics compare to InflaRx?

Atossa Genetics (NASDAQ:ATOS) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

Atossa Genetics presently has a consensus target price of $24.50, suggesting a potential upside of 456.82%. InflaRx has a consensus target price of $7.00, suggesting a potential upside of 332.10%. Given Atossa Genetics' higher probable upside, equities research analysts plainly believe Atossa Genetics is more favorable than InflaRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Atossa Genetics had 1 more articles in the media than InflaRx. MarketBeat recorded 3 mentions for Atossa Genetics and 2 mentions for InflaRx. InflaRx's average media sentiment score of 1.79 beat Atossa Genetics' score of 0.28 indicating that InflaRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atossa Genetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
InflaRx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Atossa Genetics has higher earnings, but lower revenue than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A
InflaRx	$30K	3,903.66	-$51.63M	-$0.71	N/A

Atossa Genetics' return on equity of -84.91% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-84.91%	-72.36%
InflaRx	N/A	-88.30%	-65.77%

12.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 42.4% of InflaRx shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by insiders. Comparatively, 16.3% of InflaRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Atossa Genetics has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market. Comparatively, InflaRx has a beta of 2.42, suggesting that its stock price is 142% more volatile than the broader market.

Summary

InflaRx beats Atossa Genetics on 10 of the 15 factors compared between the two stocks.

How does Atossa Genetics compare to OnKure Therapeutics?

OnKure Therapeutics (NASDAQ:OKUR) and Atossa Genetics (NASDAQ:ATOS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

OnKure Therapeutics has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

OnKure Therapeutics' return on equity of -61.02% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-61.02%	-55.99%
Atossa Genetics	N/A	-84.91%	-72.36%

Atossa Genetics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A

OnKure Therapeutics currently has a consensus target price of $27.00, suggesting a potential upside of 544.39%. Atossa Genetics has a consensus target price of $24.50, suggesting a potential upside of 456.82%. Given OnKure Therapeutics' higher possible upside, research analysts plainly believe OnKure Therapeutics is more favorable than Atossa Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

91.0% of OnKure Therapeutics shares are held by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are held by institutional investors. 2.3% of OnKure Therapeutics shares are held by insiders. Comparatively, 9.8% of Atossa Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, OnKure Therapeutics had 1 more articles in the media than Atossa Genetics. MarketBeat recorded 4 mentions for OnKure Therapeutics and 3 mentions for Atossa Genetics. OnKure Therapeutics' average media sentiment score of 0.89 beat Atossa Genetics' score of 0.28 indicating that OnKure Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OnKure Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atossa Genetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

OnKure Therapeutics beats Atossa Genetics on 6 of the 11 factors compared between the two stocks.

Get Atossa Genetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATOS vs. The Competition

Export

Metric	Atossa Genetics	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$37.98M	$7.42B	$6.50B	$11.95B
Dividend Yield	N/A	1.19%	2.67%	5.61%
P/E Ratio	-1.37	38.62	20.85	21.87
Price / Sales	N/A	73.08	500.87	105.21
Price / Cash	N/A	25.48	43.05	54.72
Price / Book	0.96	6.93	10.43	6.70
Net Income	-$34.77M	$159.22M	$3.56B	$337.26M
7 Day Performance	-6.38%	-1.91%	-1.39%	-1.41%
1 Month Performance	-21.43%	3.26%	0.86%	1.15%
1 Year Performance	-66.87%	-2.82%	19.42%	22.61%

Atossa Genetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATOS Atossa Genetics	2.2803 of 5 stars	$4.40 -0.2%	$24.50 +456.8%	-67.8%	$37.98M	N/A	N/A	8	News Coverage
DTIL Precision BioSciences	2.7579 of 5 stars	$6.79 -2.7%	$36.33 +435.5%	+29.4%	$179.84M	$45.07M	N/A	200	Positive News Analyst Forecast
TLSA Tiziana Life Sciences	1.0357 of 5 stars	$1.37 -3.1%	N/A	-14.1%	$179.44M	N/A	N/A	8
DERM Journey Medical	2.4448 of 5 stars	$6.07 -3.8%	$13.00 +114.2%	-13.7%	$173.75M	$64.68M	N/A	90	Positive News
IFRX InflaRx	2.8697 of 5 stars	$2.19 -9.0%	$7.00 +220.4%	+95.3%	$173.50M	$29.33K	N/A	60	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATOS) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atossa Genetics (ATOS) Competitors

ATOS vs. DTIL, TLSA, DERM, IFRX, and OKUR

How does Atossa Genetics compare to Precision BioSciences?

Summary

How does Atossa Genetics compare to Tiziana Life Sciences?

Summary

How does Atossa Genetics compare to Journey Medical?

Summary

How does Atossa Genetics compare to InflaRx?

Summary

How does Atossa Genetics compare to OnKure Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATOS vs. The Competition

Atossa Genetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atossa Genetics (ATOS) Competitors

ATOS vs. DTIL, TLSA, DERM, IFRX, and OKUR

How does Atossa Genetics compare to Precision BioSciences?

Which has more volatility & risk, DTIL or ATOS?

Do analysts prefer DTIL or ATOS?

Do insiders and institutionals hold more shares of DTIL or ATOS?

Which has preferable valuation & earnings, DTIL or ATOS?

Does the media favor DTIL or ATOS?

Is DTIL or ATOS more profitable?

Summary

How does Atossa Genetics compare to Tiziana Life Sciences?

Does the media prefer TLSA or ATOS?

Is TLSA or ATOS more profitable?

Which has higher valuation & earnings, TLSA or ATOS?

Do analysts rate TLSA or ATOS?

Do institutionals and insiders hold more shares of TLSA or ATOS?

Which has more risk and volatility, TLSA or ATOS?

Summary

How does Atossa Genetics compare to Journey Medical?

Which has preferable valuation and earnings, DERM or ATOS?

Do insiders and institutionals hold more shares of DERM or ATOS?

Does the media prefer DERM or ATOS?

Do analysts rate DERM or ATOS?

Which has more risk & volatility, DERM or ATOS?

Is DERM or ATOS more profitable?

Summary

How does Atossa Genetics compare to InflaRx?

Do analysts prefer ATOS or IFRX?

Does the media favor ATOS or IFRX?

Which has higher valuation & earnings, ATOS or IFRX?

Is ATOS or IFRX more profitable?

Do institutionals and insiders have more ownership in ATOS or IFRX?

Which has more risk & volatility, ATOS or IFRX?

Summary

How does Atossa Genetics compare to OnKure Therapeutics?

Which has more risk & volatility, OKUR or ATOS?

Is OKUR or ATOS more profitable?

Which has stronger valuation & earnings, OKUR or ATOS?

Do analysts recommend OKUR or ATOS?

Do insiders & institutionals have more ownership in OKUR or ATOS?

Does the media prefer OKUR or ATOS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATOS vs. The Competition

Atossa Genetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools